MS
VERV

Maven Securities’s Verve Therapeutics VERV Stock Holding History

Maven Securities’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,556
Closed -$361K – 1282
2021
Q2 		$361K Buy
+5,556
New +$231K 0.01% 782

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Maven Securities's VERV Position: Q3 2021 in Review

Maven Securities sold out of Verve Therapeutics (VERV) in Q3 2021, closing a stake of 5,556 shares — an estimated $361K sold.

Maven Securities first reported a position in VERV in Q2 2021 and held it in 1 quarter. The position peaked at $361K in Q2 2021. 73 funds tracked by Wall St. Rank hold VERV as of Q3 2021.

  • Maven Securities reported no remaining Verve Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 5,556 Verve Therapeutics shares in Q3 2021, an estimated $361K.
  • Maven Securities first reported a position in Verve Therapeutics in Q2 2021 and held it in 1 quarter.
  • Maven Securities's Verve Therapeutics position peaked at $361K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.